Sequential steps leading to the development of a drug that specifically disrupts the IBD interactome. Various types of biosamples (blood, serum, biopsies, stools) are collected from a patient with IBD, and the derived omics datasets are analyzed in the context of the patient’s medical records to generate individual networks for each ome. These networks are then integrated by an artificial intelligence computational process to build the IBD interactome and identify its central regulator (hub). Once identified, computational medicinal chemistry is applied to develop a specific inhibitor(s) that will specifically target the hub, induce the disruption of the IBD disease module, and eliminate or hinder its pathogenic activity.